FDA approves Palifermin, a modified version of a naturally occurring human protein called keratinocyte growth factor (KGF) that is manufactured in a laboratory. Palifermin is used to reduce the chances of developing severe mucositis (injury to the cells lining the mouth) and to shorten the time with severe mucositis in patients with cancer who receive high doses of chemotherapy and radiation therapy followed by stem cell rescue.

• Labeling and regulatory history from Drugs@FD